Physician profile
Lawrence Levin
NPI 1245372887
$2,556.13
in general payments reported to CMS, 2019-2025
19 companies · $564 in 2025
The $564 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $85.04 · 2022: $332 · 2023: $654 · 2024: $633 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,851.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $848.18 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $214.80 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.63 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $185.53 | 2023-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.43 | 2022-2024 | Jardiance |
| Motiva USA, LLC | $157.13 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $141.89 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $100.54 | 2024 | Arcalyst |
| Novo Nordisk INC | $98.32 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boston Scientific Corporation | $73.63 | 2025 | Watchman Flx, Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $66.53 | 2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $58.92 | 2020-2024 | Camzyos, Eliquis |
| Regeneron Healthcare Solutions, INC. | $51.64 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $46.72 | 2024 | |
| Pfizer INC. | $43.66 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $35.64 | 2022 | |
| Alnylam Pharmaceuticals INC. | $33.59 | 2025 | Amvuttra |
| Allergan, INC. | $24.35 | 2019 | |
| Bardy Diagnostics, INC. | $15.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.